ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2012
Many patients continue using proton pump inhibitors after negative results from tests for reflux disease.
Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Proton Pump Inhibitors: Rational Use and Use-Reduction - The Windsor Workshop.Digestive diseases (Basel, Switzerland) · 2024Review
- A scientometrics analysis and visualization of refractory gastroesophageal reflux disease.Frontiers in pharmacology · 2024Article
- Holistic management of symptomatic reflux: rising to the challenge of proton pump inhibitor overuse.The British journal of general practice : the journal of the Royal College of General Practitioners · 2022Article
- Epidemiological Study Assessing the Overuse of Proton Pump Inhibitors in Lebanese Population.Middle East journal of digestive diseases · 2020Article
- The Spectrum of Reflux Phenotypes.Gastroenterology & hepatology · 2019Article
- Management of gastroesophageal reflux disease: Patient and physician communication challenges and shared decision making.World journal of clinical cases · 2018Review
- The Proton Pump Inhibitor Nonresponder: a Behavioral Approach to Improvement and Wellness.Current gastroenterology reports · 2018Review
- Perceptions of patient-centered care among Veterans with gastroesophageal reflux disease on proton pump inhibitor therapy.Patient experience journal · 2018Article
- Influence of proton pump inhibitors in the development of spontaneous bacterial peritonitis.World journal of hepatology · 2017Article
- The Quality of Care for Gastroesophageal Reflux Disease.Digestive diseases and sciences · 2017Review
- Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments.Nature reviews. Gastroenterology & hepatology · 2016Review
- Current Diagnosis and Management of Suspected Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy.Gastroenterology & hepatology · 2014Article
- New Approaches to Management of PPI-Refractory Gastroesophageal Reflux Disease.Current treatment options in gastroenterology · 2014Article
- Inhibition of lysosomal enzyme activities by proton pump inhibitors.Journal of gastroenterology · 2013Article
- Discontinuation of proton pump inhibitor therapy and the role of esophageal testing.Gastroenterology & hepatology · 2013Article
- Early referral for 24-h esophageal pH monitoring may prevent unnecessary treatment with acid-reducing medications.Surgical endoscopy · 2013Article
- Ambulatory reflux monitoring in GERD--which test should be performed and should therapy be stopped?Current gastroenterology reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsAmbulatory reflux testing is used to evaluate symptoms of gastroesophageal reflux disease (GERD) refractory to protein pump inhibitors (PPIs). We investigated the prevalence of PPI use in patients with negative results from Bravo pH or multichannel intraluminal impedance-pH (MII-pH) tests and factors that might predict the use of PPIs.
methodsWe analyzed data from patients who had undergone Bravo pH monitoring or MII-pH testing at Northwestern University, without evidence of reflux disease. Demographics, endoscopy findings, pathology results, and provider recommendations were obtained via chart review. Eligible patients (n = 90) were contacted by telephone, and a cross-sectional survey was administered with questions about symptom severity, demographics, medication use, and health behaviors. Patients were compared by current PPI use, and statistical analyses were performed by using SAS version 9.2 software.
resultsThirty-eight patients (42.2%) reported current PPI use despite a negative result from a pH study. Only 17 patients (18.9%) recalled being instructed to stop taking PPIs; chart review showed documented instructions to stop PPI therapy for 15 patients (16.7%). There were no significant differences in demographic or clinical characteristics among patients compared by current PPI use. Patients taking a PPI were more likely than those not taking a PPI to report troublesome symptoms that affected their daily life, as measured by a questionnaire for the diagnosis of GERD (the GerdQ).
conclusionsMore than 42% of patients with negative results from pH monitoring studies continue PPI therapy despite physiological data that they do not have GERD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.